Market Overview

UPDATE: Bank of America Raises PO to $99 on Amgen After Omontys Recall

Related AMGN
EC Approves Amgen's BLINCYTO for Treatment of Adults with Philadelphia Chromosome-Negative Relapsed or Refractory B-precursor Acute Lymphoblastic Leukemia
European Commission Approves Kyprolis® (carfilzomib) For Combination Use In The Treatment Of Patients With Relapsed Multiple Myeloma
Premarket Biotech Digest: CTI BioPharma Undervalued, Shire's New Bid, BioMarin's DMD Drug Review (Seeking Alpha)

In a report published Monday, Bank of America reiterated a Neutral rating on Amgen (NASDAQ: AMGN), and raised its price objective from $97 to $99.

Bank of America wrote, "This weekend, AFFY/Takeda announced they were recalling all lots of their erythropoesis stimulating agent (ESA) Omontys from the market due to serious hypersensitivity reactions associated with the first infusion (0.2% total hypersensitivity, including approx 5 deaths). All patients previously taking Omontys are instructed to discontinue use. This news follows dialysis provider Fresenius' decision <2 weeks ago to close the Omontys pilot program. As we mentioned at that time, our AMGN model assumed Omontys as the preferred ESA at Fresenius starting in April. Given the recall, we are now increasing AMGN's ESA share in our model (2013 Epogen sales from $1.54B to $1.82B), bringing our total 2013 revenue up to $18.4B, and we view AMGN's 2013 $17.8-$18.2B revenue guidance as overly conservative."

Amgen closed Friday at $86.82.

Latest Ratings for AMGN

Nov 2015Piper JaffrayUpgradesOverweight
Sep 2015NomuraMaintainsBuy
Sep 2015UBSUpgradesNeutralBuy

View More Analyst Ratings for AMGN
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Analyst Ratings


Related Articles (AMGN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters